53 / 74 · 0:54 · Original AXON film
Pemvidutide
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Two primary endpoints
Pemvidutide research shows why a trial can have more than one important result. The IMPACT study assessed liver inflammation and scarring as distinct outcomes. [1]
IMPACT | 24-week analysis
This randomized phase two study enrolled 212 people with biopsy-confirmed MASH and moderate-to-advanced fibrosis. Its published analysis assessed two primary endpoints at 24 weeks. [1]
MASH endpoint met; fibrosis endpoint not met
Pemvidutide met the endpoint of MASH resolution without worsening fibrosis. It did not meet the separate endpoint of fibrosis improvement without worsening MASH at that time. [1]
Report both results
Both findings belong in the summary. Longer follow-up matters, and one favorable biopsy endpoint does not establish prevention of liver failure or overall long-term safety. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Noureddin et al. (2025): Safety and efficacy of pemvidutide versus placebo for MASH, IMPACT 24-week results →212 participants, F2/F3 MASH, dual biopsy endpoints, positive MASH-resolution endpoint and nonsignificant fibrosis-improvement endpoint at 24 weeks.
